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Transplant Complications
The Lesser of 2 Evils*
Wayne C. Levy, MD, Todd Dardas, MD, MS
Seattle, Washington
Survival after cardiac transplantation continues to improve,
and many transplant recipients are able to re-enter the
workforce. The 2010 ISHLT report identifies the median
survival among heart transplant recipients as 13 years for
those patients living beyond the first year of transplant and
10 years overall (1). Functional status among transplant
recipients remains relatively good, with 90% of patients
having a Karnofsky Index of 80% or more and 50% of
working-age recipients re-entering the workforce (1). Al-
though transplantation remains an excellent option for
those with advanced heart failure, improving both short-
and long-term survival and quality of life remains an
important goal.
See page 1036
In this issue of the Journal, Patlolla et al. (2) analyze the
ffect of pre-transplantation symptomatic cerebrovascular
isease (sCVD) on post-transplantation mortality, morbid-
ty, and functional status. Their analysis included all heart
ecipients at least 40 years of age from 1994 to 2006. sCVD
as recorded by the listing center and included events
efore and during transplantation registration. The unad-
usted rates of post-transplantation stroke (4.0% vs. 1.4%,
 0.001) and mortality (8.9% vs. 7.4%) were higher
mong patients with pre-transplantation sCVD. The in-
reased risk of stroke was preserved after multivariate
djustment (hazard ratio [HR]: 2.41; 95% confidence inter-
al [CI]: 2.02 to 2.87), although the association between
eath and sCVD was not preserved after adjusting for other
actors (HR: 1.08; 95% CI: 0.98 to 1.2). The occurrence of
unctional decline, defined as a Karnofsky Index score
80% at all successive follow-up visits, was higher for those
ith sCVD (annualized incidence 3.7% vs. 3.0%; multivar-
ate HR: 1.21; 95% CI: 1.03 to 1.42) compared with those
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disclose.ithout sCVD. Although the Organ Procurement and
ransplant Network (OPTN) database is one of the largest
nd most detailed databases for patients with advanced
eart failure, the authors note the limitation of the OPTN
atabase to identify the type and clinical severity of sCVD.
he authors conclude that sCVD must be taken in context
ith other comorbidities and should remain a relative
ontraindication to transplantation listing, which is well
upported by their thoughtful analysis.
A history of cerebrovascular disease among heart failure
atients is common, but has not consistently been identified
s an independent risk factor for death. Lee et al. (3)
dentified prevalent cerebrovascular disease among 17% to
2% of patients hospitalized with heart failure (HF),
hereas 7% to 12% of the ambulatory patients in the
HARM (Candesartan in Heart failure Assessment of
eduction in Mortality and morbidity) studies had cardio-
ascular disease (CVD) (4). In the EFFECT (Enhanced
eedback for Effective Cardiac Treatment study) multivar-
ate mortality model, CVD increased the relative risk of
eath by 1.43-fold at 30 days (p 0.01) and by 1.36-fold at
year (p  0.03), whereas a history of stroke was not
tatistically significant in the CHARM program’s multivar-
ate survival model or in follow-up of patients receiving
mplantable cardioverter-defibrillators in Canada (3–5).
he inconsistent link between sCVD and HF death results
rom the high proportion of patients with HF who die of
ump failure and sudden cardiac death (62% in the SCD-
eFT [Sudden Cardiac Death-Heart Failure Trial]) and
he smaller proportion (18% in the SCD-HeFT) who die of
oncardiac vascular events, such as stroke (6). HF is also
ssociated with a higher incidence of stroke compared with
he general population (HR: 2.9 vs. general population,
.8% to 3.2% over 5 years), and older data suggest an inverse
elationship between ejection fraction and thromboembolic
troke (HR: 1.18 for each 5% decrease in ejection fraction,
 0.03) (7,8).
sCVD, diabetes, ischemic etiology, and ventricular assist
evice (VAD) support were found to be important predic-
ors of stroke among post-transplantation patients in the
urrent study. The authors demonstrate that the greatest
ingle risk factor for post-transplantation stroke is previous
CVD. However, other risk factors in combination or alone
ay quickly approximate the risk of sCVD as a single factor.
sing estimates from the current study, a registrant with a
AD and diabetes mellitus type 2 (estimated HR for stroke:
.3) would have almost the same relative risk of post-
ransplantation stroke as registrant with sCVD (HR: 2.41;
5% CI: 2.0 to 2.9). If we accept that a high stroke risk is
ufficient to defer listing for transplantation, then an equi-
able risk assessment for stroke would necessarily include
ther factors with a comparable risk of post-transplantation
troke.
Compared with the hospitalized patients in the EFFECTegistry, in which the prevalence of CVD was 17% to 22%,
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transplantation sCVD of 6% (3). The rate of stroke was 4%
in those with sCVD and 1.4% in those without sCVD,
suggesting a lower incidence of stroke post-transplantation
than before transplantation. The absolute difference in
prolonged and poor functional status between those with
known sCVD and those without sCVD is only 0.7% or 1.21
times the risk of dysfunction in the non-sCVD group. We
can infer from these data that a significant amount of
patient selection occurs before transplantation listing that
limits the impact of sCVD in the post-transplantation
population. This practice is consistent with current guide-
lines and expert recommendations, which emphasize the
need to consider the severity of symptoms when cerebro-
vascular disease is present (9). When considering the high
risk of death among transplantation registrants, of whom
90% underwent transplantation from status 1A or 1B in
2008, and the absence of an association between post-
transplantation death and pre-transplantation sCVD, the
small difference in functional status decline associated with
sCVD seems acceptable (10).
The authors also report a dramatic reduction in the
number of strokes among transplant recipients that occur by
era, with a 54% reduction in the most recent era. The risk
of stroke among the REMATCH (Randomized Evaluation
of MEchanical Assistance for the Treatment of Congestive
HEart Failure) study was 5%, which is similar to the
post-transplant risk of stroke among those with prior sCVD
(11).
The increase in left ventricular assist device (LVAD) use
over time may affect post-transplantation stroke rates. More
than 50% of all status 1A registrants are on VAD support at
transplantation. Stroke was frequently seen with first-
generation volume-displacement VADs, and performing a
transplantation in those on VAD support produced a 53%
higher risk of stroke post-transplantation. The REMATCH
stroke rate among patients on LVAD support was 19% per
year (11), which has decreased to 13% per year with
axial-flow devices (12). The rate of stroke is lower post-
transplantation than during VAD support, making trans-
plantation more attractive than LVAD support with regard
to stroke outcomes with current LVADs.
Stroke can be a potentially devastating morbidity among
both those with HF or those who have received a transplant
to ameliorate the profound symptoms associated with end-
stage HF. The transplantation process maximizes survival
and quality of life for HF patients with the limited resource
of available donor hearts. The small difference in long-term mdisability between those with and without pre-transplantation
sCVD suggests adequate stewardship for candidate selec-
tion among transplantation programs. In the current era, the
rates of stroke post-transplantation are lower than rates
among those with severe HF and LVAD support. The
current analysis is a novel assessment of stroke risk among
transplant recipients and supports recommendations of
treating a history of cerebrovascular disease as a relative
contraindication to cardiac transplantation.
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